HC Wainwright Has Negative Opinion of HRMY FY2026 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) – Investment analysts at HC Wainwright lowered their FY2026 earnings per share estimates for shares of Harmony Biosciences in a research report issued on Thursday, November 12th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of $3.37 for the year, down from their previous estimate of $3.52. HC Wainwright currently has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $3.55 per share. HC Wainwright also issued estimates for Harmony Biosciences’ Q4 2026 earnings at $0.73 EPS, Q2 2027 earnings at $1.02 EPS, Q3 2027 earnings at $1.21 EPS, Q4 2027 earnings at $1.46 EPS, FY2027 earnings at $4.50 EPS, FY2028 earnings at $6.06 EPS, FY2029 earnings at $5.90 EPS and FY2030 earnings at $7.30 EPS.

Several other research analysts have also recently issued reports on HRMY. Wolfe Research initiated coverage on Harmony Biosciences in a research note on Wednesday, August 26th. They issued an “outperform” rating and a $60.00 price target for the company. Ladenburg Thalmann & Co. Inc. began coverage on Harmony Biosciences in a research report on Thursday, October 15th. They set a “buy” rating and a $55.00 price objective for the company. WBB Securities upgraded shares of Harmony Biosciences to a “hold” rating in a report on Friday, October 23rd. Wall Street Zen downgraded shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a research report on Sunday, November 8th. Finally, Weiss Ratings lowered shares of Harmony Biosciences from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, November 9th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $48.00.

View Our Latest Analysis on Harmony Biosciences

Harmony Biosciences Stock Performance

Shares of NASDAQ HRMY traded down $0.04 during midday trading on Friday, hitting $33.76. 844,891 shares of the company’s stock were exchanged, compared to its average volume of 1,221,212. Harmony Biosciences has a twelve month low of $25.90 and a twelve month high of $43.49. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.44 and a quick ratio of 3.42. The firm has a market cap of $1.98 billion, a P/E ratio of 11.18, a PEG ratio of 0.36 and a beta of 1.00. The stock’s 50 day moving average price is $38.65 and its 200-day moving average price is $34.62.

Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported $0.81 earnings per share for the quarter, missing the consensus estimate of $1.09 by ($0.28). The company had revenue of $268.92 million during the quarter, compared to analyst estimates of $272.05 million. Harmony Biosciences had a return on equity of 18.55% and a net margin of 18.05%. Harmony Biosciences’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period in the prior year, the business earned $1.08 earnings per share.

Insider Activity at Harmony Biosciences

In related news, insider Kumar Budur sold 35,852 shares of the firm’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $43.05, for a total value of $1,543,428.60. Following the transaction, the insider directly owned 13,115 shares in the company, valued at approximately $564,600.75. This trade represents a 73.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Over the last quarter, insiders sold 72,406 shares of company stock worth $3,108,520. Corporate insiders own 11.00% of the company’s stock.

Hedge Funds Weigh In On Harmony Biosciences

A number of hedge funds have recently made changes to their positions in HRMY. Farther Finance Advisors LLC lifted its position in shares of Harmony Biosciences by 166.7% during the third quarter. Farther Finance Advisors LLC now owns 816 shares of the company’s stock worth $32,000 after purchasing an additional 510 shares in the last quarter. Nykredit A S bought a new stake in Harmony Biosciences in the second quarter valued at approximately $33,000. Signature Equity Partners LLC acquired a new position in Harmony Biosciences in the third quarter valued at about $37,000. Hantz Financial Services Inc. raised its holdings in Harmony Biosciences by 32.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,401 shares of the company’s stock worth $55,000 after buying an additional 345 shares during the period. Finally, Signaturefd LLC boosted its stake in Harmony Biosciences by 200.0% in the 3rd quarter. Signaturefd LLC now owns 1,686 shares of the company’s stock worth $66,000 after purchasing an additional 1,124 shares during the period. Institutional investors and hedge funds own 86.23% of the company’s stock.

Top Harmony Biosciences Stories

Here are a few of the latest stories about HRMY:

About Harmony Biosciences

(Get Free Report)

Harmony Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for people living with rare neurological diseases. The company’s work centers on therapies intended to address significant unmet medical needs. Its lead product, WAKIX (pitolisant), is approved in the United States to treat excessive daytime sleepiness or cataplexy in adults and pediatric patients aged 6 years and older with narcolepsy. Harmony launched WAKIX in the United States in 2019. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony primarily serves the U.S. market.

See Also

Earnings History and Estimates for Harmony Biosciences (NASDAQ:HRMY)

Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.